We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for VMA

News   Apr 26, 2010

 
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for VMA
 
 
 

RELATED ARTICLES

Male Birth Control Pill Passes Human Safety Tests

News

A new male birth control pill passed tests of safety and tolerability when healthy men used it daily for a month, and it produced hormone responses consistent with effective contraception, according to researchers at two institutions testing the drug.

READ MORE

Treating Diabetes in Older Adults: Simpler Medication Regimens, Looser Glycemic Targets

News

Simplifying medication regimens and tailoring glycemic targets in older adults with diabetes improves adherence and avoids treatment-related complications, according to a Clinical Practice Guideline issued today by the Endocrine Society.

READ MORE

Drug Designed to Treat Opioid Cravings Begins Clinical Trial Testing

News

Researchers at the University of Maryland School of Medicine (UMSOM) Institute of Human Virology (IHV) are collaborating with scientists at the National Institutes of Health to test an experimental drug to curb opioid cravings.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE